Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapeutic progress. III: Diabetic nephropathy

S R Maxwell1, N J Gittoes

  • 1Department of Medicine, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK.

Journal of Clinical Pharmacy and Therapeutics
|October 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacology and Therapeutics Education in the European Union Needs Harmonization and Modernization: A Cross-sectional Survey Among 185 Medical Schools in 27 Countries.

Clinical pharmacology and therapeutics·2017
Same author

National Osteoporosis Society practical clinical guideline on vitamin D and bone health.

Maturitas·2014
Same author

Fear of medication side effects is a barrier to optimal osteoporosis care.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2014
Same author

A short note on the discipline of Clinical Pharmacology.

International journal of clinical pharmacology and therapeutics·2009
Same author

Local and systemic glucocorticoid metabolism in inflammatory arthritis.

Annals of the rheumatic diseases·2008
Same author

Doctors and the public concord in their acceptance of antihypertensive drug treatment.

Journal of human hypertension·2006
Same journal

Impact of pharmacist-initiated educational interventions on improving medication reconciliation practice in geriatric inpatients during hospital admission in Vietnam.

Journal of clinical pharmacy and therapeutics·2022
Same journal

Evaluation of off-label anti-vascular endothelial growth factor and steroid implant medication uses in macular edema due to retinal vein occlusion in Turkey.

Journal of clinical pharmacy and therapeutics·2022
Same journal

A descriptive analysis of pharmacological management of aggression and/or agitation in patients with traumatic brain injury in a Southwest Virginia inpatient population.

Journal of clinical pharmacy and therapeutics·2022
Same journal

Effects of caregiver counselling on medication persistence and adherence in patients with dementia at a pharmacist-managed clinic: A pilot study.

Journal of clinical pharmacy and therapeutics·2022
Same journal

The 50% and 95% effective doses of remimazolam tosilate with adjuvant sufentanil for sedation in patients with liver cirrhosis undergoing oesophagogastric varices screening endoscopy.

Journal of clinical pharmacy and therapeutics·2022
Same journal

Tumour necrosis factor inhibitor combined with intravenous immunoglobulin and heparin for treatment of recurrent spontaneous abortion: A two-centre, retrospective, cohort study.

Journal of clinical pharmacy and therapeutics·2022
See all related articles

Diabetic nephropathy can lead to kidney failure. Angiotensin converting enzyme (ACE) inhibitors show strong evidence in slowing or arresting the progression of diabetic nephropathy, preserving kidney function.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic nephropathy is a leading cause of end-stage renal failure, impacting quality of life and increasing mortality.
  • Established diabetic nephropathy is often considered irreversible, with current treatments primarily focused on delaying progression.
  • Significant financial burden associated with end-stage renal disease necessitates exploring renoprotective strategies.

Purpose of the Study:

  • To review the current literature on the renal protective effects of angiotensin converting enzyme (ACE) inhibitors in diabetic nephropathy.
  • To evaluate the efficacy of ACE inhibitors in slowing or arresting the progression of renal function deterioration in diabetic patients.

Main Methods:

  • Systematic review of existing literature on ACE inhibitor use in diabetic nephropathy.

Related Experiment Videos

  • Analysis of studies investigating the impact of ACE inhibitors on renal function in diabetic patients, with or without hypertension.
  • Inclusion of data on microproteinuric stages for assessing early intervention efficacy.

    • Main Results:

    • Strong evidence supports the use of ACE inhibitors in slowing the progression of diabetic nephropathy.
    • ACE inhibitors demonstrate efficacy in preserving renal function, irrespective of hypertensive status.
    • Early detection and intervention with ACE inhibitors in the microproteinuric stage may arrest disease progression.

    Conclusions:

    • ACE inhibitors represent a key therapeutic strategy for managing diabetic nephropathy.
    • Renal function preservation and potential arrest of disease progression are achievable with ACE inhibitors.
    • Timely intervention in early stages of diabetic nephropathy is crucial for long-term renal health.